Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 359

Sort by

Sort Order Select

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

Roberta S. Azevedo, Elias Jabbour, Hagop M Kantarjian, Sravanthi Lavu, Sanam Loghavi, Nitin Jain, Koji Sasaki, Rebecca Garris, Koichi Takahashi, Farhad Ravandi, Nicholas J. Short

Blood blood.2025030498.

https://doi.org/10.1182/blood.2025030498

Published: 2025

Includes: Supplemental data

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial

Blood (2025) 146 (Supplement 1): 237.

https://doi.org/10.1182/blood-2025-237

Published: 2025

Journal Articles

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Christopher Mill, Warren Fiskus, John Davis, Christine Birdwell, Hanxi Hou, Claes Wahlestedt, Jayastu Senapati, Koji Sasaki, Sanam Loghavi, Branko Cuglievan, Tapan Kadia, Naval Daver, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2025-1500

Published: 2025

Journal Articles

Hypomethylation agent improves late-stage megakaryocyte maturation in MDS

Yue Wei, Yue Lyu, Koji Sasaki, Ziyi Li, Hong Zheng, Yue Lu, Marcos Estecio, Abhinav Jain, Hui Yang, Kelly Chien, Ian Bouligny, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 196.

https://doi.org/10.1182/blood-2025-196

Published: 2025

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Sara Nofal, Jennifer Marvin-Peek, Sanam Loghavi, Jayastu Senapati, Bofei Wang, Fadi Haddad, Nicholas Short, Naval Daver, Ghayas Issa, Koji Sasaki, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Ehsan Irajizad, Hussein Abbas

Blood (2025) 146 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2025-3503

Published: 2025

Journal Articles

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Vanthana Bharathi, Ian Bouligny, Emmanuel Almanza, Alex Bataller, Alexandre Bazinet, Wei-Ying Jen, Niranjan Khaire, Koji Sasaki, Danielle Hammond, Courtney DiNardo, Gautam Borthakur, Tapan Kadia, Naval Daver, Ghayas Issa, Musa Yilmaz, Kelly Chien, Guillermo Montalban-Bravo, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2025-5648

Published: 2025

Journal Articles

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Ziyi Li, Kelly Chien, Yue Lyu, Koji Sasaki, Ian Bouligny, Yue Wei, Guillermo Montalban-Bravo, Sanam Loghavi, Alex Bataller, Uday Popat, Hagop Kantarjian, Alexandre Bazinet, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5644.

https://doi.org/10.1182/blood-2025-5644

Published: 2025

Journal Articles

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo, Kelly Chien, Danielle Hammond, Ian Bouligny, Jayastu Senapati, Koji Sasaki, Ghayas Issa, Nicholas Short, Tapan Kadia, Rashmi Kanagal-Shamanna, Sanam Loghavi, Guilin Tang, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2025-5641

Published: 2025

Journal Articles

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

Blood (2025) 146 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2025-3867

Published: 2025

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Blood (2025) 146 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2025-3848

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 487.

https://doi.org/10.1182/blood-2025-487

Published: 2025

Journal Articles

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Fadi Haddad, Hagop Kantarjian, Sara Dellasala, Ghayas Issa, Tapan Kadia, Jayastu Senapati, Rita Khouri, Nicholas Short, Courtney DiNardo, Nitin Jain, Hussein Abbas, Kelly Chien, Anwesha Ray, Naveen Pemmaraju, Farhad Ravandi, Guillermo Garcia-Manero, Koji Sasaki, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5564.

https://doi.org/10.1182/blood-2025-5564

Published: 2025

Journal Articles

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

Sankalp Arora, Koji Sasaki, Nicholas Short, Nitin Jain, Farhad Ravandi, Fadi Haddad, Jayastu Senapati, Guillermo Montalban-Bravo, Alexandre Bazinet, Rita Khouri, Rebecca Garris, Hagop Kantarjian, Elias Jabbour

Blood (2025) 146 (Supplement 1): 759.

https://doi.org/10.1182/blood-2025-759

Published: 2025

Journal Articles

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Mahesh Swaminathan, Alexandre Bazinet, Koji Sasaki, Dan Fox, James Hill, Alex Bataller, Kelly Chien, Guillermo Montalban-Bravo, Danielle Hammond, Michelle Hildebrandt, Ian Bouligny, Wei-Ying Jen, Tapan Kadia, Koichi Takahashi, Courtney DiNardo, Elias Jabbour, Naval Daver, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2025-4634

Published: 2025

Journal Articles

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Blood (2025) 146 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2025-4613

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial

Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML

Hypomethylation agent improves late-stage megakaryocyte maturation in MDS

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only